Immunotherapy can reawaken T cells to destroy tumour cells. Modelling of tumour and T-cell interactions suggests why certain tumour cells are targeted and improves predictions of immunotherapy outcome.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Biomarker Research Open Access 26 August 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Balachandran, V. P. et al. Nature 551, 512–516 (2017).
Łuksza, M. et al. Nature 551, 517–520 (2017).
Robins, H. Curr. Opin. Immunol. 25, 646–652 (2013).
Sharma, P. & Allison, J. P. Science 348, 56–61 (2015).
Schumacher, T. N. & Hacohen, N. Curr. Opin. Immunol. 41, 98–103 (2016).
Carreno, B. M. et al. Science 348, 803–808 (2015).
Ott, P. A. et al. Nature 547, 217–221 (2017).
Sahin, U. et al. Nature 547, 222–226 (2017).
Rights and permissions
About this article
Cite this article
Sarkizova, S., Hacohen, N. How T cells spot tumour cells. Nature 551, 444–446 (2017). https://doi.org/10.1038/d41586-017-07267-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/d41586-017-07267-9
This article is cited by
-
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Biomarker Research (2020)
-
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Nature Reviews Cancer (2019)
